03:12 PM EST - Medicenna Therapeutics Corp. : Announced today that half the patients in the ongoing Phase 2b study of MDNA55 in recurrent glioblastoma have been recruited and the data to date demonstrate solid safety results and early signals of efficacy based on the findings of the Safety Review and Clinical Advisory Committees, comprised of key opinion leaders and study investigators. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.13 at $8.02.
